Cytek Biosciences, Inc. (CTKB)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$4.700.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CTKB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -24.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 6.0% |
Growth built into the price is above our model estimate.
The price assumes 30.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
CTKB — litigation filed
Dated 2026-08-24
Other Events. On August 21, 2026, the Company announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in the Company’s favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents…
Why it matters: Hitting this revenue target shows strong growth. It matches what management expects.
Supportive ifTotal revenue for Q3 2026 is reported at $50 million or higher.
Worry ifTotal revenue for Q3 2026 is reported below $48 million.
Why it matters: The earnings report will show if revenue growth is slowing. This is key for future performance.
Worry ifEarnings report shows revenue growth below the median for the sector.
Less concerning ifEarnings report shows revenue growth above the median for the sector.
Why it matters: A drop in sector revenue growth could signal broader challenges for Cytek. It may affect market confidence.
Worry ifSector revenue growth reported below its median.
Less concerning ifSector revenue growth remains above its median.
Why it matters: High use of new products like Cytek Borealis shows that innovation is working.
Supportive ifSales of Cytek Borealis exceed 100 units within the first quarter after launch.
Worry ifSales of Cytek Borealis are below 50 units within the first quarter after launch.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$170 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $562 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,294 loss on $10,000 · 42.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Better operating income is important for Cytek. It shows they can control costs well.
Supportive ifOperating loss in Q2 2026 narrows to less than -$15 million.
Worry ifOperating loss in Q2 2026 worsens beyond -$20 million.
Why it matters: Good results in court can help investor confidence and lower legal risks.
Supportive ifA good ruling in patent court raises confidence in product offerings.
Worry ifA bad ruling in patent court can lead to higher legal costs or product limits.
Why it matters: News about new products shows that Cytek is making progress. This helps them compete.
Watch forThere is news about new products or upgrades to current products.
Also watch forNo updates on product pipeline or delays in product launches.
Why it matters: A rise in gross profit indicates better cost management and product demand. This is vital for future growth.
Supportive ifGross profit exceeds $25 million in Q2.
Worry ifGross profit remains below $20 million in Q2.
Why it matters: The Global Sales and Services leader leaving may hurt sales.
Worry ifSales stay stable or improve even with the leadership change.
Less concerning ifSales drop a lot after the executive leaves.
Why it matters: Updates on product launches show Cytek's focus on new ideas. This affects future sales.
Watch forManagement shares news about new products launched in Q2.
Also watch forNo updates on new product launches in Q2.
Why it matters: Growing the installed base is key for increasing future revenue from service and reagents. It shows market acceptance of Cytek's products.
Supportive ifInstalled base increases by more than 150 units in the next quarter.
Worry ifInstalled base growth falls below 100 units in the next quarter.
Why it matters: Changes in leadership can change sales strategies. This can affect revenue growth.
Watch forSales performance improves in Q2 2026 compared to Q1 2026.
Also watch forSales performance declines in Q2 2026 compared to Q1 2026.
Why it matters: Management has set a revenue target of $205M to $212M for 2026. Confirmation supports growth expectations.
Supportive ifManagement confirms Q3 revenue guidance remains within the $205M to $212M range.
Worry ifManagement lowers the revenue guidance to below $205M.
Why it matters: The installed base grew from 3,789 to 3,933 units in Q2. Continued growth indicates strong demand.
Supportive ifInstalled base increases by more than 100 units in Q3.
Worry ifInstalled base growth stalls or declines in Q3.
Why it matters: Recurring revenue reached 35% of total revenue in Q2. Maintaining this level shows strong service growth.
Supportive ifRecurring revenue percentage stays at or above 35% in Q3.
Worry ifRecurring revenue percentage drops below 35% in Q3.
Why it matters: Recent lawsuit results can change Cytek's market position and finances. Good results may boost confidence.
Watch forThere are more positive jury decisions in current patent lawsuits.
Also watch forBad results in current patent lawsuits.